Baxter International Inc (BAX) Stock Price, Quote & News

Company Profile

Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; administrative sets; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed sy...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 224 948 2000

Website: www.baxter.com

Address:

One Baxter Parkway, Deerfield, United States

PrivateProfiteersAnalyst Dec. 25 at 2:34 PM

Actionable Trade Alert for $BAX: Market Context: $BAX is currently trading at $19.11, showing bullish momentum with an RSI of 60.13, indicating potential for further upward movement without being overbought. The stock is above its 30-day moving average (MA30) of $18.64 but below the 50-day moving average (MA50) of $19.5, suggesting a possible breakout. Directional Bias: The price is near the upper end of the 60-day range (high of $24.27 and low of $17.4), indicating room for growth. The ATR of 0.46 suggests moderate volatility, making it suitable for trading. Trade Plan: - Suggested Entry: $19.11 - Stop Loss: $18.50 (3.2% below entry) - Take Profit Targets: - Target 1: $20.50 (7.3% gain) - Target 2: $21.75 (8.6% gain) - Target 3: $22.40 (17.0% gain) This plan offers a solid risk-reward ratio with potential for over 17% ROI on the third target. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com

0 · Reply

OfficialStocktwitsUser Dec. 25 at 3:24 AM

$BAX RSI: 60.13, MACD: -0.0370 Vol: 0.37, MA20: 18.85, MA50: 19.49 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

SPYmyQQQ Dec. 22 at 6:33 PM

🚀 New Signal ✅ 🏛️ $BAX 🗓️ Dec 22, 2025 💵 Entry: $19.11 🎯 Target (Opt.): $19.54 (+2.26%) 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

SparkyReturns Dec. 22 at 5:21 PM

$ICU Dammit I should keep quiet. Now I gotta chase it to get more shares. This device will be a game-changer for kidney disease, sepsis, cardio-renal, and any disease with hyper-inflammation and cytokine storm. GL longs! $DVA $BAX $MCK $BDX

0 · Reply

trading_momentum_x Dec. 20 at 5:31 AM

$BAX (Baxter) => Range bound recovery, no trend yet Technical Stabilized post-gap down, but below declining long MAs RSI 50 = neutral MACD rolling over = momentum fading near range highs Fundamental Turnaround story still early; earnings visibility limited No strong catalyst near-term Bottom Line Neutral / range trade Buy interest only near $18 support Upside capped unless it clears $20–21 with volume

0 · Reply

PrivateProfiteersAnalyst Dec. 19 at 4:29 PM

Actionable Trade Alert for $BAX: Market Context: $BAX is currently trading at $19.07, showing a stable position within its recent range. The RSI at 54.35 indicates a neutral momentum, suggesting potential for upward movement. The stock is positioned between its 60D high of $24.27 and low of $17.4, giving room for growth. Directional Bias: The MA30 at $18.5 is below the current price, indicating short-term bullish sentiment. However, the MA50 at $19.77 suggests resistance ahead. Given the RSI and proximity to the 60D high, we anticipate a bullish trend. Trade Plan: - Suggested Entry: $19.10 - Stop Loss: $18.50 (3.14% risk) - Take Profit Targets: 1. $20.50 (7.38% gain) 2. $21.50 (11.5% gain) 3. $22.40 (17.3% gain) With a solid risk-reward ratio, this trade plan aims for a minimum of 17% ROI on the third target. https://privateprofiteers.com

0 · Reply

Gemineye Dec. 18 at 5:46 PM

$BAX Common shares….no time limits

0 · Reply

PrivateProfiteersAnalyst Dec. 17 at 3:15 AM

Actionable Trade Alert for $BAX: Market Context: $BAX is currently trading at $19.05, showing a stable position within a defined range. The 60D high is $24.27 and the low is $17.4, indicating potential for upside movement. Directional Bias: With an RSI of 55.2, $BAX is neither overbought nor oversold, suggesting room for upward momentum. The MA30 at $18.42 is below the current price, indicating short-term bullish sentiment, while the MA50 at $19.91 acts as a resistance level. Trade Plan: - Suggested Entry: $19.05 - Stop Loss: $18.50 (Risking $0.55) - Take Profit Targets: 1. $20.50 (ROI: 7.6%) 2. $21.75 (ROI: 8.9%) 3. $22.35 (ROI: 17.9%) This strategy targets a potential 17% ROI on the third take profit while maintaining a reasonable risk-reward ratio. Monitor price action closely around MA50 for confirmation. https://privateprofiteers.com

0 · Reply

TACP Dec. 15 at 6:54 PM

$BAX I'm going to take a chance on BAX. I like the setup now on this extremely beaten down stock. It looks like a rotation into the healthcare sector. BTO BAX Jan 16 $20C and Feb 20 $20C. There's a nice Call Wall at $20.

0 · Reply

ZacksResearch Dec. 15 at 4:08 PM

Is $BAX's 34.4% YTD drop a buying opportunity? 🤔 Despite flat trading after the ASHP 2025 meeting, Baxter's smart pump data shows promise: 50.3% drop in hard limit alerts, 30.4% in soft alerts, and 38.1% fewer single-step rate change alerts. Could this drive adoption, nursing efficiency, and growth? Full analysis here 👉 https://www.zacks.com/stock/news/2804498/bax-highlights-emr-integrated-smart-pumps-boost-patient-safety-care?cid=sm-stocktwits-2-2804498-body-24853&ADID=SYND_STOCKTWITS_TWEET_2_2804498_BODY_24853

0 · Reply

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Baxter International and Molina Healthcare on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

MOH

Dec 12, 2025, 10:32 AM EST - 13 days ago

DOC HOLLYWOOD: A Psychiatrist Takes 3rd Place with Baxter's Brain at the American Film Market Pitch Conference

Dec 11, 2025, 10:21 AM EST - 14 days ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Baxter International

Dec 11, 2025, 8:30 AM EST - 14 days ago

Baxter Presents Real-World Data at American Society of Health System Pharmacists Meeting Demonstrating Smart Infusion Pump Electronic Medical Record (EMR) Integration May Improve Patient Safety and Nursing Bedside Productivity

Dec 10, 2025, 1:00 PM EST - 15 days ago

Scrooge: 5 Stocks That Could Ruin Your Santa Rally

AXON BAH SG WLK

Dec 8, 2025, 12:49 PM EST - 17 days ago

BAX INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Baxter International

Dec 7, 2025, 2:11 PM EST - 18 days ago

Macquarie Value Fund Q3 2025 Sales And Purchases

ALL CAG DIS MMC PLD PPG WFC

Dec 4, 2025, 6:07 PM EST - 20 days ago

Bragar Eagel & Squire, P.C. Reminds James Hardie and Baxter International Investors to Contact the Firm Regarding Their Rights

JHX

Dec 4, 2025, 4:15 PM EST - 20 days ago

Baxter Announces Pricing of Tender Offers for 2.600% Senior Notes Due 2026 and 1.915% Senior Notes Due 2027

Dec 4, 2025, 7:51 AM EST - 21 days ago

Baxter Announces Early Tender Results for 2.600% Senior Notes Due 2026 and 1.915% Senior Notes Due 2027

Dec 2, 2025, 3:23 PM EST - 22 days ago

Baxter International Inc. (BAX) Presents at Evercore 8th Annual Healthcare Conference Transcript

Dec 1, 2025, 5:56 PM EST - 23 days ago

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Baxter International

Nov 24, 2025, 10:56 AM EST - 4 weeks ago

Artisan Value Income Fund Q3 2025 Contributors And Detractors

LRCX NVT PII PM

Nov 19, 2025, 4:15 PM EST - 5 weeks ago

Baxter Announces Increase in Maximum Tender Cap for 1.915% Senior Notes Due 2027

Nov 19, 2025, 8:54 AM EST - 5 weeks ago

Baxter Announces Tender Offers for 2026 Notes and 2027 Notes

Nov 18, 2025, 10:28 AM EST - 5 weeks ago

Baxter International Inc. (BAX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 11, 2025, 4:30 PM EST - 6 weeks ago

Baxter Declares Quarterly Dividend

Nov 10, 2025, 8:15 AM EST - 6 weeks ago

BAXTER INTERNATIONAL INC. (NYSE: BAX) DEADLINE ALERT Bernstein Liebhard LLP Reminds Baxter International Inc. Investors of Upcoming Deadline

Nov 7, 2025, 8:45 AM EST - 6 weeks ago

The Baxter Foundation Announces $2.6M Grant to Advance STEM Education in Chicagoland Through Partnership With Northwestern University

Nov 5, 2025, 6:00 PM EST - 7 weeks ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 15, 2025 in Baxter International, Inc. Lawsuit – BAX

Nov 4, 2025, 4:58 PM EST - 7 weeks ago

Watch These Stocks Falling 10% Or More

AJG ARE BRO CAVA CMG DECK ERIE

Nov 4, 2025, 8:30 AM EST - 7 weeks ago

Don't Write Off Baxter Just Yet

Oct 30, 2025, 2:54 PM EDT - 2 months ago

Baxter Trims Annual Outlook Again, Stock Hits 52-Week

Oct 30, 2025, 11:29 AM EDT - 2 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Baxter International

Oct 30, 2025, 11:26 AM EDT - 2 months ago

Baxter International Inc. (BAX) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 8:27 AM EDT - 2 months ago

Medical products maker Baxter cuts annual profit forecast on persistent hurricane impact

Oct 30, 2025, 7:15 AM EDT - 2 months ago

Baxter Reports Third-Quarter 2025 Results

Oct 28, 2025, 9:38 AM EDT - 2 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Baxter International

Oct 28, 2025, 2:20 AM EDT - 2 months ago

Artisan Partners Q3 2025 Position Updates

ALGN CNC

Oct 27, 2025, 8:45 AM EDT - 2 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 15, 2025 in Baxter International, Inc. Lawsuit - BAX

Oct 23, 2025, 1:11 PM EDT - 2 months ago

BAX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Baxter International

Oct 22, 2025, 7:22 AM EDT - 2 months ago

BAX STOCK NOTICE: Baxter International Inc. Investors with Losses may have been Affected by Fraud – Contact BFA Law before December 15 Lawsuit Deadline

PrivateProfiteersAnalyst Dec. 25 at 2:34 PM

0 · Reply

OfficialStocktwitsUser Dec. 25 at 3:24 AM

0 · Reply

SPYmyQQQ Dec. 22 at 6:33 PM

🚀 New Signal ✅ 🏛️ $BAX 🗓️ Dec 22, 2025 💵 Entry: $19.11 🎯 Target (Opt.): $19.54 (+2.26%) 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

SparkyReturns Dec. 22 at 5:21 PM

0 · Reply

trading_momentum_x Dec. 20 at 5:31 AM

0 · Reply

PrivateProfiteersAnalyst Dec. 19 at 4:29 PM

0 · Reply

Gemineye Dec. 18 at 5:46 PM

$BAX Common shares….no time limits

0 · Reply

PrivateProfiteersAnalyst Dec. 17 at 3:15 AM

0 · Reply

TACP Dec. 15 at 6:54 PM

0 · Reply

ZacksResearch Dec. 15 at 4:08 PM

0 · Reply

ZacksResearch Dec. 15 at 3:08 PM

Patient safety + efficiency upgrades — this is why $BAX is back in focus 🏥💡 Baxter highlighted EMR-integrated smart pumps that reduce safety alerts and speed IV setup, supported by real-world data from over a million infusions presented at ASHP 2025. See how this tech is improving care delivery 👉 https://www.zacks.com/stock/news/2804498/bax-highlights-emr-integrated-smart-pumps-boost-patient-safety-care?cid=sm-stocktwits-2-2804498-teaser-24842&ADID=SYND_STOCKTWITS_TWEET_2_2804498_TEASER_24842

0 · Reply

PrivateProfiteersAnalyst Dec. 15 at 6:48 AM

Actionable Trade Alert for $BAX: Market Context: $BAX is currently trading at $19.15, showing bullish momentum but nearing overbought conditions with an RSI of 62.0. The price is above the 30-day moving average (MA30) of 18.36 but below the 50-day moving average (MA50) of 20.08, indicating mixed short to medium-term signals. The 60-day high of 24.27 presents a potential resistance level, while the low of 17.4 suggests strong support. Directional Bias: The bullish sentiment is supported by the recent price action above MA30 and the proximity to the 60D high. However, caution is warranted given the RSI nearing overbought territory. Trade Plan: - Suggested Entry: $19.15 - Stop Loss: $18.50 (3.4% below entry) - Take Profit Targets: - TP1: $20.00 (4.4% gain) - TP2: $21.50 (12.5% gain) - TP3: $22.50 (17.4% gain) This setup offers a favorable risk-reward ratio, aiming for a minimum of 17% ROI on TP3. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com

0 · Reply

OnlyFibs Dec. 15 at 12:18 AM

$BAX is a battleground between value and lawsuits. ⚖️ Technically trying to double-bottom at $18.75, but the descending channel on the 8h is relentless. 📉 Fresh class-action news regarding Novum pumps is the heavy anchor. ⚓ Bulls need to reclaim $20 to signal the "Vantive" spin-off value is real. Below $18.75 = flushed to $17. #hovdid

0 · Reply

OfficialStocktwitsUser Dec. 12 at 4:10 PM

$BAX RSI: 63.13, MACD: -0.2784 Vol: 0.48, MA20: 18.44, MA50: 20.07 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

StockConsultant Dec. 12 at 2:39 PM

$BAX Baxter stock, watch for an upside gap breakout at https://stockconsultant.com/?BAX

0 · Reply

PrivateProfiteersAnalyst Dec. 11 at 11:42 PM

Actionable Trade Alert for $BAX: Market Context: $BAX is currently trading at $18.57, showing a strong upward momentum but is approaching overbought conditions with an RSI of 65.05. The stock is above its 30-day moving average (MA30) of $18.35, indicating bullish sentiment. However, it remains below the 50-day moving average (MA50) of $20.15, suggesting potential resistance ahead. Directional Bias: The recent high of $24.27 indicates a significant upside potential, while the 60-day low of $17.4 provides a solid support level. The ATR of 0.5 suggests moderate volatility, allowing for reasonable price movements. Trade Plan: - Suggested Entry: $18.60 - Stop Loss: $17.90 (3.77% risk) - Take Profit Targets: 1. $20.00 (7.66% gain) 2. $21.50 (15.46% gain) 3. $21.75 (17.00% gain) This trade plan offers a favorable risk-reward ratio with a potential ROI of over 17% on the third target. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com

0 · Reply

OfficialStocktwitsUser Dec. 11 at 3:19 PM

$BAX RSI: 64.93, MACD: -0.3916 Vol: 0.44, MA20: 18.39, MA50: 20.15 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

PrivateProfiteersAnalyst Dec. 10 at 3:46 AM

Actionable Trade Alert for $BAX: Market Context: $BAX is currently trading at $18.16, showing a neutral RSI of 50.12. The stock is positioned between its 60D high of $24.27 and low of $17.4, indicating potential for upward movement given the proximity to the low. The MA30 at $18.63 is above the current price, suggesting short-term resistance, while the MA50 at $20.34 indicates a longer-term bullish trend if surpassed. Directional Bias: The neutral RSI suggests indecision, but the stock's recent low and proximity to the MA30 indicate a potential bounce back towards the MA50. Trade Plan: - Suggested Entry: $18.20 - Stop Loss: $17.40 (below recent low) - Take Profit Targets: 1. $19.00 (4.4% ROI) 2. $20.00 (10% ROI) 3. $21.25 (17.5% ROI) This plan allows for a balanced risk-reward scenario while targeting significant upside potential. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com

0 · Reply

PrivateProfiteersAnalyst Dec. 8 at 11:33 PM

Actionable Trade Alert for $BAX: Market Context: $BAX is currently trading at $18.36, exhibiting a neutral to bullish sentiment with an RSI of 56.83, suggesting potential upward momentum. The stock is below its 30-day moving average (MA30) of $18.8 and significantly below its 50-day moving average (MA50) of $20.43, indicating a possible reversal opportunity. Directional Bias: The RSI indicates that the stock is not overbought, leaving room for upward movement. The recent high of $24.27 provides a strong resistance level, while the 60-day low of $17.4 offers solid support. Trade Plan: - Suggested Entry: $18.40 - Stop Loss: $17.80 (3.3% risk) - Take Profit Targets: 1. $20.00 (8.7% ROI) 2. $21.50 (16.8% ROI) 3. $21.50 (17.7% ROI) The third target aligns with a potential breakout scenario, providing an attractive risk-reward ratio. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com

0 · Reply

PrivateProfiteersAnalyst Dec. 6 at 2:34 AM

Actionable Trade Alert for $BAX: Market Context: $BAX is currently trading at $18.48, positioned below its 30-day moving average (MA30) of $19.11 and 50-day moving average (MA50) of $20.57. The RSI at 47.8 indicates a neutral momentum, suggesting potential for upward movement if bullish sentiment develops. Directional Bias: With the 60-day high at $24.52 and low at $17.4, the stock is near the lower end of this range. The ATR of 0.56 indicates moderate volatility, allowing for reasonable price movement. Trade Plan: - Suggested Entry: $18.50 - Stop Loss: $17.40 (below recent low) - Take Profit Targets: 1. $20.00 (8.1% ROI) 2. $21.00 (13.2% ROI) 3. $21.67 (17.5% ROI) This trade plan allows for a strategic entry with a favorable risk-reward ratio, targeting significant upside potential while managing downside risk effectively. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com

0 · Reply

PrivateProfiteersAnalyst Dec. 5 at 10:08 PM

0 · Reply

IreneMaryland463 Dec. 5 at 2:44 PM

$BAX operates in global medical-devices and healthcare supply — areas where data accuracy and compliance are critical. AERT’s workflow automation reduces operational risk and ensures controlled migrations. https://www.nasdaq.com/press-release/aeries-technologys-consulting-led-automation-practice-delivers-measurable-impact-0

0 · Reply

Market Cap	9.73B
Revenue (ttm)	10.64B
Net Income (ttm)	-649.00M
EPS (ttm)	N/A
PE Ratio	7.88
Forward PE	8.04
Profit Margin	-6.10%
Debt to Equity Ratio	1.32

Volume	2,312,600
Avg Vol	8,375,698
Day's Range	N/A - N/A
Shares Out	514.06M
Stochastic %K	39%
Beta	0.61
Analysts	Sell
Price Target	$22.14